34º Congresso Mineiro de Cardiologia
Acesse o site do congresso
1º Dia - 7/10/25
2º Dia - 7/11/25
3º Dia - 7/12/25

Ampliando as indicações dos SGL2i e dos GLP1-Ras Voltar

Flávia Coimbra Pontes Maia

Simpósio Conjunto SMC e DEIC (Cardiomiopatias) - Marcelo Imbroinisi Bittencourt e Estevão Lanna Figueiredo

Artigo Autor(es) Referência
Encouraging the prescribing of SGLT2i and GLP-1RA medications to reduce cardiovascular and renal risk in patients with type 2 diabetes: Rationale and design of a randomized controlled trial. Haff Nancy, Horn Daniel M, Bhatkhande Gauri, Sung Meekang, Colling Caitlin, Wood Wendy, Robertson Ted, Gaposchkin Daniel, Simmons Leigh, Yang Judy, Yeh James, Crum Katherine L, Hanken Kaitlin E, Lauffenburger Julie C, Choudhry Niteesh K American heart journal. 2025 Jul; 285(Jul):39-51. doi: 10.1016/j.ahj.2025.02.007. pii: S0002-8703(25)00038-9.
GLP-1 receptor agonists beyond diabetes management. eClinicalMedicine EClinicalMedicine. 2024 Dec; 78(Dec):103021. doi: 10.1016/j.eclinm.2024.103021. pii: 103021.
Glucagon-like peptide-1 receptor: mechanisms and advances in therapy. Zheng Zhikai, Zong Yao, Ma Yiyang, Tian Yucheng, Pang Yidan, Zhang Changqing, Gao Junjie Signal transduction and targeted therapy. 2024 Sep; 9(Sep):234. doi: 10.1038/s41392-024-01931-z. pii: 234.
Incorporating SGLT2i and GLP-1RA for Cardiovascular and Kidney Disease Risk Reduction: Call for Action to the Cardiology Community. Nelson Adam J, Pagidipati Neha J, Aroda Vanita R, Cavender Matthew A, Green Jennifer B, Lopes Renato D, Al-Khalidi Hussein, Gaynor Tanya, Kaltenbach Lisa A, Kirk Julienne K, Lingvay Ildiko, Magwire Melissa L, O'Brien Emily C, Pak Jonathan, Pop-Busui Rodica, Richardson Caroline R, Reed Monica, Senyucel Cagri, Webb Laura, McGuire Darren K, Granger Christopher B Circulation. 2021 Jul; 144(Jul):74-84. doi: 10.1161/CIRCULATIONAHA.121.053766. pii: .
Integrated Management of Cardiovascular-Renal-Hepatic-Metabolic Syndrome: Expanding Roles of SGLT2is, GLP-1RAs, and GIP/GLP-1RAs. Theodorakis Nikolaos, Nikolaou Maria Biomedicines. 2025 Jan; 13(Jan):doi: 10.3390/biomedicines13010135. pii: 135.
Optimizing SGLT2 inhibitor and GLP-1 RA prescribing in high-risk patients with diabetes: a Department of Veterans Affairs quality improvement intervention. Yun Shira, Hurren Kathryn, Holleman Rob, Klamerus Mandi, Tremblay Adam, Sussman Jeremy B BMC primary care. 2025 Mar; 26(Mar):78. doi: 10.1186/s12875-025-02709-0. pii: 78.
SGLT2i in heart failure: can their benefits be expanded across the entire spectrum of ejection fraction? Requena-Ibáñez Juan Antonio, Santos-Gallego Carlos G, Badimón Juan José Revista espanola de cardiologia (English ed.). 2022 Oct; 75(Oct):833-841. doi: 10.1016/j.rec.2022.04.019. pii: S1885-5857(22)00182-7.
The expanding role of SGLT2 inhibitors beyond glucose-lowering to cardiorenal protection. Brown Emily, Wilding John P H, Alam Uazman, Barber Thomas M, Karalliedde Janaka, Cuthbertson Daniel J Annals of medicine. 2021 Dec; 53(Dec):2072-2089. doi: 10.1080/07853890.2020.1841281. pii: .
Use of Sodium-Glucose Cotransporter 2 Inhibitors and Glucagonlike Peptide-1 Receptor Agonists in Patients With Diabetes and Cardiovascular Disease in Community Practice. Nanna Michael G, Kolkailah Ahmed A, Page Courtney, Peterson Eric D, Navar Ann Marie JAMA cardiology. 2023 Jan; 8(Jan):89-95. doi: 10.1001/jamacardio.2022.3839. pii: .
Nenhuma revista foi definida para este congresso.